TABLE 1.
Patients’ clinical featuresa
| Patient | Gender/age | Date of hospitalization | Severe COVID pneumonia | Positive rectal cultures for KPC-E | Infection with Kp-KPC in preceding mo | Previous use of CZA | Main treatment for the CZA-resistant episode | Outcome |
|---|---|---|---|---|---|---|---|---|
| 1 | M/53 | 03-21-2021 | Y | Y | Y | Y | No atb. catheter removal | Discharge |
| 2 | M/47 | 05-27-2021 | Y | Y | N | N | No atb. colonization | Discharge |
| 3 | F/71 | 05-28-2021 | Y | Y | N | N | MEM + AMK | Discharge |
| 4 | M/46 | 05-22-2021 | Y | Y | N | N | AMK | Discharge |
| 5 | F/36 | 05-21-2021 | Y | Y | Y | Y | MEM + AMK | Deathb |
| 6 | M/73 | 06-07-2021 | N | Y | Y | Y | CZA + AMK, then MEM + AMK + FOF | Discharge |
a
F, female; M, male; Y, yes; N, no; CZA, ceftazidime-avibactam; No atb., no antibiotics were administered for these episodes because either removal of catheter or colonization was assumed; MEM, meropenem; AMK, amikacin; FOF, fosfomycin; KPC-E, KPC-producing Enterobacterales; KPC-Kp, KPC-producing Klebsiella pneumoniae. Both KPC-E colonization and KPC-Kp were considered in the preceding month of CZA-resistant isolation.
b
Death occurred more than 30 days after CZA-resistant infection, being nonrelated to it.